The standard case for the fund is to invest in rounds with 3 partakers. Despite the Sprout BioVentures, startups are often financed by BioAdvance. The meaningful sponsors for the fund in investment in the same round are Viva Biotech, Viva BioInnovator, Lumira Ventures.
Among the most popular fund investment industries, there are Software, Gaming. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Mebias Discovery
The common things for fund are deals in the range of 1 - 5 millions dollars. The high activity for fund was in 2019. The fund is constantly included in 2-6 deals per year.
Related Funds
| Fund Name | Location |
| Derui Qiyuan Venture Capital | China, Guangdong, Shenzhen |
| Encubate Holdings | Atlanta, Georgia, United States |
| Forage Capital Partners | Alberta, Calgary, Canada |
| Junpu | Japan, Tokyo |
| Leukemia & Lymphoma Society | New York, United States, White Plains |
| Midas Ventures | Brazil, São Paulo, Sao Paulo |
| PRIME Impact Fund | Cambridge, Massachusetts, United States |
| venVelo | Florida, United States, Winter Park |
| Zhuji Hongyi Cultural Industry Investment | China, Zhejiang, Zhuji |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AmacaThera | $10M | 22 Feb 2021 | Old Toronto, Ontario, Canada | ||
AmacaThera | $2M | 03 Oct 2019 | Canada, Ontario |
– AmacaThera announced the close of an oversubscribed $10.3m Series A financing to support development of AMT-143, the company’s lead clinical asset, and pipeline expansion.
– The Series A round was led by Lumira Ventures and includes a global investor syndicate of existing investors, Viva BioInnovator and Sprout BioVentures, as well as new investors, BDC Capital Women in Technology (WIT) Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures, and MaRS IAF.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AmacaThera | $10M | 22 Feb 2021 | Old Toronto, Ontario, Canada | ||
AmacaThera | $2M | 03 Oct 2019 | Canada, Ontario |
